Schizophrenia Differential Diagnoses
- Author: Frances R Frankenburg, MD; Chief Editor: Glen L Xiong, MD more...
Diagnostic ConsiderationsOther psychiatric illnessesAnatomic lesionsMetabolic illnessesEndocrine disordersInfectious illnessesMiscellaneous disordersVitamin deficiency
Disorders to be considered in the differential diagnosis of schizophrenia include the following:
Other psychiatric illnesses
Schizophrenia and bipolar affective disorder (manic-depressive illness) may be difficult to distinguish from each other. Patients with manic-depressive illness predominantly have disturbances in their affect or mood. Psychotic symptoms may be prominent during a mania or depression.
In classic manic-depressive illness, the psychotic symptoms are congruent with mania or depression, and the person has periods of euthymia (normal mood) with no psychotic symptoms between the episodes. However, some patients have periods of psychotic symptoms in the absence of depression or mania. In these cases, schizoaffective disorder is diagnosed.
In delusional disorder, the person has a variety of paranoid beliefs, but these beliefs are not bizarre and are not accompanied by any other symptoms of schizophrenia. For example, a person who is functioning well at work but becomes unreasonably convinced that his or her spouse is having an affair has a delusional disorder rather than schizophrenia.
Schizotypal personality disorder is characterized by a pervasive pattern of discomfort in close relationships with others, along with the presence of odd thoughts and behaviors. The oddness in this disorder is not as extreme as that observed in schizophrenia.
In schizoid personality disorder, the person has difficulty and lack of interest in forming close relationships with others and prefers solitary activities. No other symptoms of schizophrenia are present.
In paranoid personality disorder, the person is distrustful and suspicious of others. No actual delusions or other symptoms of schizophrenia are present.
Substance abuse is discussed below.
In rare cases, brain tumors may be confused with a psychotic illness. Because brain tumors are potentially lethal but treatable, it is important to consider brain imaging studies for every person with a new onset of a psychotic illness or, perhaps, a marked change in symptoms.
Subdural hematomas can manifest as changes in mental status. Intracranial bleeding should be considered in patients who report head trauma or who, for whatever reason, are not able to provide a clear history. Brain imaging may be appropriate in these cases.
Idiopathic calcification of the basal ganglia is a rare disorder that tends to present as psychosis in patients who become symptomatic early in adulthood; those presenting later in life typically present with dementia and a motor system disorder. Schizophrenialike symptoms may precede the onset of intellectual deterioration and extrapyramidal motor disturbances.
Wilson disease, also known as hepatolenticular degeneration, is a disorder of the metabolism of copper.
It is an autosomal recessive illness. The first psychiatric symptoms are often vague changes in behavior during adolescence. It is primarily a liver disease.
Laboratory findings include increased urinary levels of copper and low serum levels of copper and ceruloplasmin. Kayser-Fleischer rings (copper deposits around the cornea) can sometimes be seen. The diagnosis is usually confirmed by finding increased hepatic copper at biopsy.
Porphyrias are disorders of heme biosynthesis. Acute intermittent porphyria can present with psychiatric symptoms. Patients may have a family history of psychosis. The psychiatric symptoms may be associated with electrolyte changes, peripheral neuropathy, and episodic severe abdominal pain. Abnormally high levels of porphyrins in a 24-hour urine collection confirm the diagnosis.
Patients with hypoxemia or electrolyte disturbances may present with confusion and psychotic symptoms. Hypoglycemia or hyperglycemia can produce confusion and irritability and may be mistaken for psychosis.
Delirium from whatever cause (eg, metabolic or endocrine disorders) is an important condition to consider, especially in the elderly or hospitalized patient. The clinical hallmarks are decreased attention span and a waxing-and-waning type of confusion.
Severe hypothyroidism or hyperthyroidism can be associated with psychotic symptoms. Hypothyroidism is usually associated with depression, which if severe may be accompanied by psychotic symptoms. A hyperthyroid person is typically depressed, anxious, and irritable.
Both adrenocortical insufficiency (Addison disease) and hypercortisolism (Cushing syndrome) may result in mental status changes. Both disorders also produce physical signs and symptoms that can suggest the diagnosis. In addition, most patients with Cushing syndrome will have a history of long-term steroid therapy for a medical illness.
Hypoparathyroidism or hyperparathyroidism can on occasion be associated with vague mental status changes. These are related to abnormalities in serum calcium concentrations.
Many infectious illnesses, such as influenza, Lyme disease, hepatitis C, and any of the encephalitides (particularly those caused by the herpesviruses), can cause mental status changes such as depression, anxiety, irritability, or psychosis. Elderly people with pneumonias or urinary tract infections may become confused or frankly psychotic.
The infectious illnesses of particular interest are the following:
Chronic Lyme disease
Creutzfeldt-Jakob disease (CJD)
Neurosyphilis can be divided into the following 3 categories:
Patients with general paresis may present with behavioral changes, psychosis or dementia. The diagnosis can be suggested by a history of exposure, personality changes, and pupillary changes (Argyll Robertson pupil).
The Venereal Disease Research Laboratory (VDRL) and rapid plasma reagin (RPR) tests are nontreponemal tests that use antigens to detect antibodies to Treponema pallidum. Because antibodies decline during the disease, these tests have a high false-negative rate. If neurosyphilis is strongly suspected, more specific treponemal tests, such as the fluorescent-treponemal antibody absorption test (FTA-ABS), can be useful.
HIV penetrates the blood-brain barrier early in the course of the infection and thus can cause a number of mental status changes, particularly dementia or other neuropsychological impairment. In addition, patients infected with HIV are at risk for opportunistic infections, such as neurosyphilis, toxoplasmosis, cryptococcal meningitis, progressive multifocal leukoencephalopathy, cytomegalovirus encephalopathy, and tuberculous meningitis, all of which can lead to mental status changes.
Persons infected with HIV are also at risk for primary central nervous system lymphoma. Many medications used to treat HIV may cause mental status changes. Finally, persons infected with HIV are at risk for nutritional deficiencies that also contribute to mental status changes.
Patients with cerebral abscesses rarely have psychotic symptoms, but brain imaging should be considered to rule out this treatable possibility. Immunosuppressed persons and people living in or traveling in underdeveloped countries are particularly at risk.
A few patients with chronic Lyme disease may have problems of fatigue and difficulty thinking. There is much controversy about this diagnosis.
Prions cause the rare CJD, one of the transmissible spongiform encephalopathies. The disease usually occurs in people older than 50 years and is marked by rapid deterioration, dementia, abnormal electroencephalographic complexes, and myoclonic jerks.
A variant of this illness, vCJD, is the human form of bovine spongiform encephalopathy (so-called mad cow disease). Fewer than 200 cases of vCJD have occurred worldwide, and as of 2003, only 2 cases had occurred in the United States. Unlike CJD, vCJD seems to affect people aged 20-40 years. It begins with behavioral changes. In several cases, the patient was diagnosed with schizophrenia before the diagnosis of vCJD was made.
Multiple sclerosis is notoriously difficult to diagnose in its early stages. The physical symptoms may be overlooked, and psychological symptoms may occasionally be an early feature.
Huntington disease is a neurodegenerative disorder marked by neuronal loss throughout the brain, especially in the striatum. This is an autosomal dominant disorder, the gene for which has been located on chromosome 4. A family history is essential to making the diagnosis.
The occurrence of choreoathetoid movements well before exposure to antipsychotic agents is suggestive of Huntington disease. About three-fourths of patients with Huntington disease initially present with psychiatric symptoms.
Alzheimer disease, the most common cause of dementia, is marked by loss of memory and personality, other cognitive, and mood changes in elderly persons. As the illness progresses the person may develop psychotic symptoms.
Dementia with Lewy bodies is the second most common type of dementia. Patients present with fluctuating mental status and prominent psychiatric symptoms, including depression and visual hallucinations. These patients are reported to do poorly when treated with antipsychotic drugs.
Lipid storage disorders include metachromatic leukodystrophy, adrenoleukodystrophy, GM2 gangliosidosis, and ceroid lipofuscinosis. These illnesses usually occur in childhood but may occasionally come to medical attention during adolescence. Patients may present with psychiatric symptoms such as cognitive deterioration and changes in personality. Patients may be diagnosed with schizophrenia until the neurologic symptoms of these illnesses become more prominent.
Malignancies (typically, bronchial oat-cell carcinoma) can occasionally lead to dramatic mental status changes early in their course and before they have been diagnosed or have metastasized to the brain. The etiology is not clear, but is thought to be due to a variety of antibodies. Various paraneoplastic neurologic syndromes have been described, including subacute cerebellar degeneration, encephalopathy with brainstem involvement, diffuse encephalopathies, and limbic encephalopathy or encephalitis. In young women, ovarian tumors can be associated with limbic encephalitis, presumably due to anti-NMDAR (n-methyl-d-aspartate receptor) antibodies. In cases of limbic encephalopathy or encephalitis, the patient usually has a subacute onset of symptoms such as seizures, memory loss, confusion, headache, and hallucinations.
Patients with a seizure or ictal disorder, especially temporal lobe epilepsy, may occasionally display odd behavior before, during, or after a seizure. Aura and ictal symptoms can include hallucinations, disturbances of memory, or affective and cognitive changes. Ictal and postictal phenomena can include complex motor abnormalities.
Patients with systemic lupus erythematosus, typically young women, may present with psychiatric symptoms, such as psychosis or cognitive deficit, in association with unexplained fever or joint pain. The diagnosis can be suggested by the physical findings of malar flush and the laboratory findings of anemia, renal dysfunction, elevated erythrocyte sedimentation rate (ESR), and, most specifically, elevated antinuclear antibody (ANA) levels.
Presenting features of systemic vasculitides (eg, polyarteritis nodosa, Churg-Strauss syndrome, Wegener granulomatosis, and Behçet disease) may include personality changes. Other symptoms, such as weight loss and fever, usually occur. Magnetic resonance imaging (MRI) shows characteristic lesions of vasculitis.
Heavy metal toxicity may cause changes in personality, thinking, or mood. Occupational exposure is the usual source of heavy metal toxicity, but cases have also resulted from ingestion of herbal medications contaminated with heavy metals.
Many medications have been associated with mental status changes, especially the following:
Corticosteroids (psychosis, depression, or mania)
Levodopa (hallucinations or insomnia)
Interferon alfa (depression)
Beta blockers, including those in eye drops (depression)
Substance abuse (eg, abuse of alcohol, cocaine, opiates, psychostimulants, or hallucinogens) not uncommonly leads to disturbed perceptions, thought, mood, and behavior. The anabolic steroids used by body builders and athletes can lead to psychotic symptoms. Anticholinergic medications can lead to delirium, especially if abused.
A deficiency of vitamin B-1 (thiamine) can occur in people who rely on alcohol for calories or patients with advanced malignancies or malabsorption syndromes. Acute and severe thiamine depletion can lead to Wernicke encephalopathy, marked by oculomotor disturbances, ataxia, and confabulation. If this condition is left untreated, Korsakoff psychosis may develop. Wernicke encephalopathy is a common and underdiagnosed cause of chronic cognitive impairment in people with alcoholism.
Deficiency of vitamin B-12, folate, or both may produce depression or dementia. Very rarely, these deficiencies may result in delusional thinking.
Brief Psychotic Disorder
Mental Disorders Secondary to General Medical Conditions
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Press; 2000.
Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000 Jan. 157(1):16-25. [Medline].
Tamminga CA, Stan AD, Wagner AD. The hippocampal formation in schizophrenia. Am J Psychiatry. 2010 Oct. 167(10):1178-93. [Medline].
Mattai A, Hosanagar A, Weisinger B, Greenstein D, Stidd R, Clasen L. Hippocampal volume development in healthy siblings of childhood-onset schizophrenia patients. Am J Psychiatry. 2011 Apr. 168(4):427-35. [Medline].
Sigmundsson T, Suckling J, Maier M, et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry. 2001 Feb. 158(2):234-43. [Medline].
Ellison-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res. 2009 Mar. 108(1-3):3-10. [Medline].
McIntosh AM, Owens DC, Moorhead WJ, Whalley HC, Stanfield AC, Hall J, et al. Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. Biol Psychiatry. 2011 May 15. 69(10):953-8. [Medline].
Olabi B, Ellison-Wright I, McIntosh AM, et al. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry. 2011 Jul 1. 70(1):88-96. [Medline].
Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996 Jan-Feb. 3(5):241-53. [Medline].
Cioffi CL. Modulation of NMDA receptor function as a treatment for schizophrenia. Bioorg Med Chem Lett. 2013 Jul 19. [Medline].
Drexhage RC, Weigelt K, van Beveren N, Cohen D, Versnel MA, Nolen WA, et al. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int Rev Neurobiol. 2011. 101:169-201. [Medline].
Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Rev Neurother. 2007 Jul. 7(7):789-96. [Medline].
Selten JP, Cantor-Graae E, Kahn RS. Migration and schizophrenia. Curr Opin Psychiatry. 2007 Mar. 20(2):111-5. [Medline].
Bourque F, van der Ven E, Malla A. A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. Psychol Med. 2011 May. 41(5):897-910. [Medline].
Kirkbride J, Coid JW, Morgan C, et al. Translating the epidemiology of psychosis into public mental health: evidence, challenges and future prospects. J Public Ment Health. 2010 Jun. 9(2):4-14. [Medline].
Kety SS, Wender PH, Jacobsen B, et al. Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Replication of the Copenhagen Study in the rest of Denmark. Arch Gen Psychiatry. 1994 Jun. 51(6):442-55. [Medline].
Brooks M. New Schizophrenia Genes Identified. Medscape Medical News. Jul 22 2014. [Full Text].
Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014 Jul 24. 511(7510):421-7. [Medline].
Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005 May 15. 57(10):1117-27. [Medline].
Shifman S, Johannesson M, Bronstein M, et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. 2008 Feb. 4(2):e28. [Medline].
Wratten NS, Memoli H, Huang Y, Dulencin AM, Matteson PG, Cornacchia MA, et al. Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am J Psychiatry. April/2009. 166:434-41. [Medline].
O'Brien NL, Way MJ, Kandaswamy R, et al. The functional GRM3 Kozak sequence variant rs148754219 affects the risk of schizophrenia and alcohol dependence as well as bipolar disorder. Psychiatr Genet. 2014 Jul 18. [Medline].
Bassett AS, Costain G, Fung WL, Russell KJ, Pierce L, Kapadia R, et al. Clinically detectable copy number variations in a Canadian catchment population of schizophrenia. J Psychiatr Res. 2010 Nov. 44(15):1005-9. [Medline].
Bassett AS, Scherer SW, Brzustowicz LM. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am J Psychiatry. 2010 Aug. 167(8):899-914. [Medline]. [Full Text].
Owen MJ, O'Donovan MC, Thapar A, Craddock N. Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry. 2011 Mar. 198:173-5. [Medline].
Sahoo T, Theisen A, Rosenfeld JA, et al. Copy number variants of schizophrenia susceptibility loci are associated with a spectrum of speech and developmental delays and behavior problems. Genet Med. 2011 Oct. 13(10):868-80. [Medline].
Corvin AP, Morris DW, McGhee K, Schwaiger S, Scully P, Quinn J, et al. Confirmation and refinement of an 'at-risk' haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus. Mol Psychiatry. 2004 Feb. 9(2):208-13. [Medline].
Ekelund J, Hennah W, Hiekkalinna T, Parker A, Meyer J, Lönnqvist J, et al. Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol Psychiatry. 2004 Nov. 9(11):1037-41. [Medline].
Hennah W, Thomson P, McQuillin A, Bass N, Loukola A, Anjorin A, et al. DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol Psychiatry. 2009 Sep. 14(9):865-73. [Medline].
Huffaker SJ, Chen J, Nicodemus KK, Sambataro F, Yang F, Mattay V, et al. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med. 2009 May. 15(5):509-18. [Medline]. [Full Text].
Kirov G, Ivanov D, Williams NM, Preece A, Nikolov I, Milev R, et al. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. Biol Psychiatry. 2004 May 15. 55(10):971-5. [Medline].
Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry. 2001 May. 6(3):293-301. [Medline].
Morris DW, Rodgers A, McGhee KA, Schwaiger S, Scully P, Quinn J, et al. Confirming RGS4 as a susceptibility gene for schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2004 Feb 15. 125B(1):50-3. [Medline].
Schindler KM, Pato MT, Dourado A, Macedo A, Azevedo MH, Kennedy JL, et al. Association and linkage disequilibrium between a functional polymorphism of the dopamine-2 receptor gene and schizophrenia in a genetically homogeneous Portuguese population. Mol Psychiatry. 2002. 7(9):1002-5. [Medline].
Shifman S, Bronstein M, Sternfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet. 2002 Dec. 71(6):1296-302. [Medline]. [Full Text].
Steinberg S, Mors O, Børglum AD, Gustafsson O, Werge T, Mortensen PB, et al. Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry. 2011 Jan. 16(1):59-66. [Medline]. [Full Text].
Tang JX, Chen WY, He G, Zhou J, Gu NF, Feng GY, et al. Polymorphisms within 5' end of the Neuregulin 1 gene are genetically associated with schizophrenia in the Chinese population. Mol Psychiatry. 2004 Jan. 9(1):11-2. [Medline].
Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry. 2011 Apr. 16(4):429-41. [Medline].
Xu B, Roos JL, Dexheimer P, et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet. 2011 Aug 7. 43(9):864-8. [Medline].
Girard SL, Gauthier J, Noreau A, et al. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet. 2011 Jul 10. 43(9):860-3. [Medline].
Brooks M. De Novo Gene Mutations Linked to Schizophrenia. Medscape Medical News. Available at http://www.medscape.com/viewarticle/819742.. Accessed: February 4, 2014.
Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014 Jan 22. [Medline].
Lencz T, Guha S, Liu C, Rosenfeld J, Mukherjee S, Derosse P. Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nat Commun. 2013 Nov 19. 4:2739. [Medline].
Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003 Dec. 60(12):1187-92. [Medline].
Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010 Mar. 167(3):261-80. [Medline].
Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. 2004 Aug. 61 (8):774-80. [Medline].
Torrey EF, Bowler AE, Rawlings R, Terrazas A. Seasonality of schizophrenia and stillbirths. Schizophr Bull. 1993. 19(3):557-62. [Medline].
Clarke MC, Tanskanen A, Huttunen M, Whittaker JC, Cannon M. Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia. Am J Psychiatry. 2009 Sep. 166(9):1025-30. [Medline].
Anderson P. Teen Marijuana Use Linked to Earlier Psychosis Onset. Medscape Medical News. May 14 2014. [Full Text].
Haro JM, Novick D, Bertsch J, et al. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J Psychiatry. 2011 Sep. 199:194-201. [Medline].
Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ. 2011 Sep 13. 343:d5422. [Medline]. [Full Text].
Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011 Jun 15. CD002831. [Medline].
Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994 Nov 19. 344(8934):1398-402. [Medline].
Ho BC, Andreasen NC. Long delays in seeking treatment for schizophrenia. Lancet. 2001 Mar 24. 357(9260):898-900. [Medline].
Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007 Mar. 164(3):402-8. [Medline].
Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010 Aug. 167(8):987-93. [Medline].
Yücel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull. 2012 Mar. 38(2):316-30. [Medline]. [Full Text].
Brauser D. Cannabis Not the Only Illicit Drug Linked to Schizophrenia. Medscape Medical News. Available at http://www.medscape.com/viewarticle/807520. Accessed: July 17, 2013.
Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord. 1982 Sep. 4(3):173-93. [Medline].
Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010 Sep. 197(3):174-9. [Medline].
Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003 Jan. 60(1):82-91. [Medline].
Shioiri T, Shinada K, Kuwabara H, Someya T. Early prodromal symptoms and diagnoses before first psychotic episode in 219 inpatients with schizophrenia. Psychiatry Clin Neurosci. 2007 Aug. 61(4):348-54. [Medline].
Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012 May. 69(5):476-83. [Medline].
Bennett DJ, Ogloff JR, Mullen PE, et al. Schizophrenia disorders, substance abuse and prior offending in a sequential series of 435 homicides. Acta Psychiatr Scand. 2011 Sep. 124(3):226-33. [Medline].
Fazel S, Långström N, Hjern A, Grann M, Lichtenstein P. Schizophrenia, substance abuse, and violent crime. JAMA. 2009 May 20. 301(19):2016-23. [Medline].
Cummings JL, Gosenfeld LF, Houlihan JP, McCaffrey T. Neuropsychiatric disturbances associated with idiopathic calcification of the basal ganglia. Biol Psychiatry. 1983 May. 18(5):591-601. [Medline].
Rosebush PI, MacQueen GM, Clarke JT, et al. Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry. 1995 Aug. 56(8):347-53. [Medline].
Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. 1994 May. 51(5):375-82. [Medline].
Reuler JB, Girard DE, Cooney TG. Current concepts. Wernicke's encephalopathy. N Engl J Med. 1985 Apr 18. 312(16):1035-9. [Medline].
Salokangas RK. Medical problems in schizophrenia patients living in the community (alternative facilities). Curr Opin Psychiatry. 2007 Jul. 20(4):402-5. [Medline].
Brauser D. Long-term Injectable Drug Effective for Schizophrenia. Medscape Medical News. May 11 2012. [Full Text].
Cassels C. FDA Approves Once-Monthly Treatment for Schizophrenia. Medscape Medical News. Mar 1 2013. [Full Text].
Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012 May. 73(5):617-24. [Medline]. [Full Text].
Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013 Jul. 13(7):767-83. [Medline].
Lieberman JA, Stroup TS. The NIMH-CATIE Schizophrenia Study: what did we learn?. Am J Psychiatry. 2011 Aug. 168(8):770-5. [Medline].
Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006 Oct. 63(10):1079-87. [Medline].
Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, et al. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia : A Randomized Clinical Trial. JAMA Psychiatry. 2015 Jun 24. [Medline].
Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008 Mar 29. 371(9618):1085-97. [Medline].
McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 Jul. 164(7):1050-60. [Medline].
[Guideline] Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010 Jan. 36(1):71-93. [Medline]. [Full Text].
Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013 Sep. 70(9):913-20. [Medline].
Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003 May. 28(5):995-1003. [Medline].
Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. Clozapine as a first treatment for schizophrenia. Am J Psychiatry. 2003 Aug. 160(8):1514-6. [Medline].
Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007 Nov. 68(11):1751-62. [Medline].
Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011 Nov. 72(11):1439-44. [Medline].
Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011 Jul. 168(7):702-8. [Medline].
Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009 Mar. 35(2):443-57. [Medline]. [Full Text].
Honer WG, MacEwan GW, Gendron A, Stip E, Labelle A, Williams R, et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012 Jan. 73(1):13-20. [Medline].
Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013 Nov 18. 11:CD006625. [Medline].
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011 Mar 3. 364(9):842-51. [Medline].
Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. Schizophr Bull. 2013 Jan 2. [Medline].
Subotnik KL, Nuechterlein KH, Ventura J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011 Mar. 168(3):286-92. [Medline].
Takeuchi H, Suzuki T, Remington G, et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull. 2013 Sep. 39(5):993-8. [Medline]. [Full Text].
Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001 Nov. 158(11):1774-82. [Medline].
Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. 2011 Feb. 168(2):193-201. [Medline].
Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007. 68 Suppl 1:20-7. [Medline].
Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010 Oct. 197(4):266-71. [Medline].
Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011 Sep. 168(9):947-56. [Medline].
Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res. 2012 Jun. 138(1):54-7. [Medline].
Hägg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. Lancet. 2000 Apr 1. 355(9210):1155-6. [Medline].
Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic drugs and venous thromboembolism. Lancet. 2000 Jul 15. 356(9225):252. [Medline].
Lowry F. Psychotropic Drugs Can Reduce Bone Mass in Kids. Medscape Medical News. Jun 24 2014. [Full Text].
Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011 Feb. 68(2):128-37. [Medline].
[Guideline] Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010 Jan. 36(1):48-70. [Medline]. [Full Text].
Guo X, Zhai J, Liu Z, Fang M, Wang B, Wang C, et al. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry. 2010 Sep. 67(9):895-904. [Medline].
Wexler BE, Bell MD. Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophr Bull. 2005 Oct. 31(4):931-41. [Medline].
Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011 May. 168(5):472-85. [Medline].
Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry. 2012 Feb. 69(2):121-7. [Medline].
Puig O, Penadés R, Baeza I, De la Serna E, Sánchez-Gistau V, Bernardo M, et al. Cognitive remediation therapy in adolescents with early-onset schizophrenia: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2014 Aug. 53(8):859-68. [Medline].
Brooks, M. Cognitive Therapy a Viable Monotherapy for Schizophrenia?. Medscape Medical News. Available at http://www.medscape.com/viewarticle/820258. Accessed: February 19, 2014.
Morrison, Anthony P., Turkington, D., Pyle, M., et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. The Lancet. February 2014. [Full Text].
Bond GR, Drake RE. Making the Case for IPS Supported Employment. Adm Policy Ment Health. 2012 Nov 17. [Medline].
McHugo GJ, Drake RE, Xie H, Bond GR. A 10-year study of steady employment and non-vocational outcomes among people with serious mental illness and co-occurring substance use disorders. Schizophr Res. 2012 Jul. 138(2-3):233-9. [Medline].
Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010 Dec 8. CD000088. [Medline].
Hegelstad WT, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012 Apr. 169(4):374-80. [Medline].
Weiser M. Early intervention for schizophrenia: the risk-benefit ratio of antipsychotic treatment in the prodromal phase. Am J Psychiatry. 2011 Aug. 168(8):761-3. [Medline].
Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry. 2012 Jan. 200(1):22-9. [Medline].
Rosenberg O, Gersner R, Klein LD, Kotler M, Zangen A, Dannon P. Deep transcranial magnetic stimulation add-on for the treatment of auditory hallucinations: a double-blind study. Ann Gen Psychiatry. 2012 May 6. 11:13. [Medline]. [Full Text].
Levkovitz Y, Rabany L, Harel EV, Zangen A. Deep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive deficits of schizophrenia: a feasibility study. Int J Neuropsychopharmacol. 2011 Aug. 14(7):991-6. [Medline].
Cassels, C. Antipsychotic Linked to Potentially Fatal Skin Reaction. Medscape Medical News. Available at http://www.medscape.com/viewarticle/836427. Accessed: December 13, 2014.
Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med. 1991 Mar 14. 324(11):746-54. [Medline].
Brauser D. Psychosocial Interventions May Help Nip Psychosis in the Bud. Medscape Medical News. Available at http://www.medscape.com/viewarticle/829526. Accessed: August 9, 2014.
Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study. JAMA Psychiatry. Oct 8 2014.
Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009 Jan 21. CD000059. [Medline].
Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014 Nov. 75(11):1254-60. [Medline]. [Full Text].
Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014 Nov. 75(11):1254-60. [Medline].
Keller DM. Parkinsonism a major mortality risk factor in schizophrenia. Medscape Medical News. March 5, 2014. [Full Text].
Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012 Feb. 14(1):31-40. [Medline].
Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011 Jan. 198(1):51-8. [Medline]. [Full Text].
Lowry F. Rapid Rise in Cardiometabolic Risk in Early Schizophrenia. Medscape Medical News. Oct 14 2014. [Full Text].
Miklowitz DJ, O'Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, et al. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. 2014 Aug. 53(8):848-58. [Medline]. [Full Text].
Schoepf D, Uppal H, Potluri R, Heun R. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Presented at: The 22nd European Congress of Psychiatry (EPA); March 3, 2014; Munich, Germany. Abstract FC07. Eur Arch Psychiatry Clin Neurosci. 2014 Feb. 264(1):3-28. [Medline]. [Full Text].